Basic research in the laboratory of professor Håvard Attramadal at Institute for Surgical Research has uncovered the
mechanisms of action of signaling molecules critically involved in fibrotic
diseases. Based on these novel findings and advanced biotechnology research scientist
Ole Jørgen Kaasbøll and professor Håvard Attramadal developed a novel drug with
pan-antifibrotic actions that potentially may be used to target several
fibrotic conditions including diseases affecting the kidney, lung and liver.
This innovation is now being commercialized by Tribune Therapeutics, a biotech
start-up company launched with seed financing from HealthCap AB and Novo
Holding, following a licensing agreement with Inven2 AS, the TTO of Oslo
University Hospital and University of Oslo. Ole Jørgen Kaasbøll has been
appointed Chief Scientific Officer of the company which is starting up in
Forskningsparken. You can read more about the company at Inven2.